Abstract
Objectives: Health costs, which are increasing at a yearly rate of 4 %, represent 11 % and thus a large share of Austria's gross domestic product (GDP). High expenditures derive from mental health care costs, including medication. In this article we investigate whether the costs and usage of psychopharmaceutic products in Austria are rising. Method: We did a descriptive analysis of the sales ...
Abstract
Objectives: Health costs, which are increasing at a yearly rate of 4 %, represent 11 % and thus a large share of Austria's gross domestic product (GDP). High expenditures derive from mental health care costs, including medication. In this article we investigate whether the costs and usage of psychopharmaceutic products in Austria are rising. Method: We did a descriptive analysis of the sales figures and number for packaging units of pharmaceutical products of ATC-classes N05 and N06 in all Austrian hospitals, pharmacies and medicine chests for the years 2006-2013. All data were provided free of charge by IMS-Health. Results: The sales volume and number of prescribed packaging units of pharmaceuticals of ATC-classes N05 and N06 increased over the time period in question. In 2013, about 25 % more packaging units were being sold than in 2006. Among the two ATC-classes, however, the indication subgroups developed differently. Expenditures increased a total of about 31 % within the period of consideration. Conclusions: The increase in psycho-pharmaceutical sales exceeds the expansion rates of other health expenditures (17.8 %). During the 9 years of observation, 25 % more psychopharmaceutical products were sold. This may result from increased prevalence of mental disorders, higher usage or an increment in prescriptions.
Altmetric